logo
Share SHARE
FONT-SIZE Plus   Neg

VIVUS Says FDA Extends Qnexa PDUFA Date

VIVUS Inc. (VVUS) said Monday that the U.S. Food and Drug Administration has extended the Prescription Drug User Fee Act date for its review of the Qnexa New Drug Application by three months from April 17 to July 17, 2012.

On April 4, following the FDA's request, VIVUS submitted the Qnexa Risk Evaluation and Mitigation Strategy, which was considered a major amendment to the NDA. The submission consisted of proposed REMS materials.

Since the receipt date was within three months of the user fee goal date, the FDA is extending the Prescription Drug User Fee Act date by three months to provide time for a full review of the submission, the company noted.

The Qnexa NDA seeks approval for the treatment of obesity, including weight loss and maintenance of weight loss for obese patients with weight-related co-morbidities such as hypertension, type 2 diabetes or dyslipidemia.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Amazon has slashed the price of 4K movies and tv shows, probably to compete with launch offer of Apple TV 4K that plans to sell 4K content at the rate of HD content. The 4K version of its set-top box is expected to be in market next week. The Securities and Exchange Commission or SEC announced Monday its two new initiatives aimed to address cyber-based threats and protect retail investors. SEC announced the creation of a Cyber Unit to focus the Enforcement Division's substantial cyber-related expertise on targeting cyber-related misconduct. The agency also established a retail strategy task force. China has largely blocked instant messaging service WhatsApp, the media reported. The disruption is said to be the latest step to tighten censorship as the country prepares for the Communist Party's congress in Beijing, which starts October 18.
comments powered by Disqus
Follow RTT